UBS lowered the firm’s price target on Zimmer Biomet (ZBH) to $86 from $88 and keeps a Sell rating on the shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet: Multi‑Year Turnaround Story Underpins Upgrade to Buy and $109 Price Target
- Zimmer Biomet assumed at Buy from Hold at TD Cowen
- Zimmer Biomet says sales growth outlook for 2026 ‘tempered’
- Zimmer Biomet price target raised to $99 from $97 at Bernstein
- Zimmer Biomet downgraded to Sell from Neutral at Goldman Sachs